Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting

NCT01101776 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT01101776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01101776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Observational
Overall status
Completed
Start date
January 31, 2010
Completion date
April 30, 2013
Enrollment
49 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis